Role of Neoadjuvant Chemotherapy on the Surgical Treatment of Locally Advanced Breast Cancer
Abd Allah, M., Abdellatif, T., Amr, W., Abdel Moneim, H., Haggag, R. (2020). Role of Neoadjuvant Chemotherapy on the Surgical Treatment of Locally Advanced Breast Cancer. EKB Journal Management System, 26(4), 640-648. doi: 10.21608/zumj.2019.14080.1283
Mai Abd El Kader Abd Allah; Tarek Ezzat Abdellatif; Wesam Mohamad Amr; Hatem Mohamad Abdel Moneim; rasha Mohamad Haggag. "Role of Neoadjuvant Chemotherapy on the Surgical Treatment of Locally Advanced Breast Cancer". EKB Journal Management System, 26, 4, 2020, 640-648. doi: 10.21608/zumj.2019.14080.1283
Abd Allah, M., Abdellatif, T., Amr, W., Abdel Moneim, H., Haggag, R. (2020). 'Role of Neoadjuvant Chemotherapy on the Surgical Treatment of Locally Advanced Breast Cancer', EKB Journal Management System, 26(4), pp. 640-648. doi: 10.21608/zumj.2019.14080.1283
Abd Allah, M., Abdellatif, T., Amr, W., Abdel Moneim, H., Haggag, R. Role of Neoadjuvant Chemotherapy on the Surgical Treatment of Locally Advanced Breast Cancer. EKB Journal Management System, 2020; 26(4): 640-648. doi: 10.21608/zumj.2019.14080.1283

Role of Neoadjuvant Chemotherapy on the Surgical Treatment of Locally Advanced Breast Cancer

Zagazig University Medical Journal
Article 14, Volume 26, Issue 4, July 2020, Page 640-648  XML PDF (733.98 K)
Document Type: Original Article
DOI: 10.21608/zumj.2019.14080.1283
View on SCiNiTO View on SCiNiTO
Authors
Mai Abd El Kader Abd Allah email 1; Tarek Ezzat Abdellatiforcid 2; Wesam Mohamad Amr2; Hatem Mohamad Abdel Moneim2; rasha Mohamad Haggagorcid 3
1General Surgery , Al Ahrar Teaching Hospital , Sharkia ,Egypt
2Department of General Surgery, Zagazig University,Sharkia,Egypt
3Department of Medical Oncology, Zagazig University, Sharkia,Egypt
Abstract
Background: In developing countries preoperative chemotherapy can reduce the size of the tumor, thus allow some patients with advanced tumors which is common the opportunity of conserving breast surgery. The aim of the study was to evaluate the efficacy of neoadjuvant chemotherapy (NC) on the possibility of breast-conserving surgery (BCS) in patients for whom mastectomy (MT) was the only accepted surgical option. Methods: thirty patients who had stage III breast cancer received neoadjuvant chemotherapy comprised of doxorubicin and cyclophosphamide, followed by surgery between 2017 and 2019. Results: thirty patients included in the study, 27(90%) presented with an invasive ductal carcinoma. The mean tumor size before NC, measured using MRI, was 37 mm (range, 20-75 mm) and 29 mm (range, 12.5-75 mm) after NC. Twenty patients (66.7%) underwent MT while ten patients (33.3%) underwent BCS. The mean follow up survival time for all patients was 32±1.2 months range (29.8-34.8) months with (95% CI; 29.8-34.8).one case (3.3%) of BCS had locoregional recurrence and three cases (10%) had distant metastasis. Patients with IDC had significant higher DFS (33.5 ±1.04) months than patients with combined IDC+ILC (20±6) months and ILC(18) months.Patients with MT had better numerical (not significant) DFS (32.25±1.5) months than patients with BCS (31.6±2.3) months. Conclusion: NC had a role in reducing the size of the tumor and could be applied in patients with advanced carcinoma. It increased the chance of BCS without affecting overall survival.
Keywords
breast cancer; Neoadjuvant chemotherapy; Locally advanced breast cancer; Breast-conserving surgery
Statistics
Article View: 350
PDF Download: 238